There are 2934 resources available
Conclusions and perspectives
Presenter: Joaquim Bellmunt
Session: Selecting and sequencing therapy in previously untreated urothelial cancer
Resources:
Slides
Webcast
Single agent immune therapy and immune combinations
Presenter: Joaquim Bellmunt
Session: Selecting and sequencing therapy in previously untreated urothelial cancer
Resources:
Slides
Webcast
Immune therapy in combination with targeted therapy
Presenter: Yohann Loriot
Session: Selecting and sequencing therapy in previously untreated urothelial cancer
Resources:
Slides
Webcast
Hereditary cancer syndrome: How to deal with in routine clinical practice
Presenter: Kevin Punie
Session: Practicing oncology: Special issues in real life
Resources:
Slides
Webcast
803 - Durable anti-tumor activity of the multi-targeted inhibitor lenvatinib in patients with advanced or metastatic thymic carcinoma; Preliminary results from a multicenter phase II (REMORA) trial.
Presenter: Shoichi Itoh
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Abstract
Slides
Webcast
3257 - A phase II study of Monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).
Presenter: Rachel Galot
Session: Proffered Paper – Head and neck cancer
Resources:
Abstract
Slides
Webcast
3250 - Personalized treatment according to geriatric assessment in 1st line recurrent and/or metastatic (R/M) Head and Neck Squamous Cell Cancer (HNSCC) patients aged 70 or over. ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials
Presenter: Joel Guigay
Session: Proffered Paper – Head and neck cancer
Resources:
Abstract
Slides
Webcast
2064 - Cisplatin reduces costs and provides more quality adjusted life years (QALYs) than cetuximab in chemoradiotherapy for patients with HPV-Positive Oropharyngeal Cancer (HPV+OPC)
Presenter: David Jones
Session: Proffered Paper – Head and neck cancer
Resources:
Abstract
Slides
Webcast
4445 - Association of tumor mutational burden with outcomes in patients with select advanced solid tumors treated with pembrolizumab in KEYNOTE-158
Presenter: Aurélien Marabelle
Session: Proffered Paper – Immunotherapy of cancer
Resources:
Abstract
Slides
Webcast
5378 - 2nd/3rd-line Nivolumab vs Nivo plus Ipilimumab in Malignant Pleural Mesothelioma: long-term results of IFCT-1501 MAPS2 phase 2R trial with a focus on hyperprogression (HPD)
Presenter: Gerard Zalcman
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Abstract
Slides
Webcast